Trials / Conditions / Recurrent Bladder Urothelial Carcinoma

Recurrent Bladder Urothelial Carcinoma

8 registered clinical trials studyying Recurrent Bladder Urothelial Carcinoma.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemo NCT04963153	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	ARID1A and/or KDM6A Mutation and CXCL13 Expression NCT04953104	M.D. Anderson Cancer Center	Phase 2
Completed	Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Blad NCT04496219	Fred Hutchinson Cancer Center	Phase 2
Completed	Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial C NCT03513952	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metasta NCT03237780	National Cancer Institute (NCI)	Phase 2
Completed	Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer NCT02844816	National Cancer Institute (NCI)	Phase 2
Withdrawn	Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treat NCT02718742	Mayo Clinic	Phase 2
Completed	Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer NCT00749892	M.D. Anderson Cancer Center	Phase 2